on Jaguar Health, Inc. (NASDAQ:JAGX)
Magdalena Biosciences Set to Present at Neuroscience Innovation Forum
Magdalena Biosciences, a joint initiative by Jaguar Health and Filament Health, will present at the Annual Neuroscience Innovation Forum in San Francisco on January 12, 2025. Dr. Karen Brunke, acting CEO of Magdalena, will discuss their botanical drug candidate, MB2500. The company plans to submit an Investigational New Drug (IND) application to the FDA in 2025, targeting mental health conditions like ADHD and schizophrenia.
MB2500 stands out due to its derivation from a plant used traditionally for its neuroprotective properties. It aims to address cognitive deficits in schizophrenia, a significant unmet medical need. With the global ADHD market estimated at $25 billion, Magdalena seeks to innovate in a sector demanding safer treatments.
The venture represents a shift in drug development, leveraging traditional plant-based medicines to quickly reach clinical studies. Magdalena plans additional IND-enabled applications in 2025, aiming for significant advancements in psychoactive plant-based therapies.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Jaguar Health, Inc. news